Substance Abuse Treatment Records
Buy and sell substance abuse treatment records data. Intake assessments, treatment modalities, relapse patterns — addiction recovery AI needs real outcome data.
No listings currently in the marketplace for Substance Abuse Treatment Records.
Find Me This Data →Overview
What Is Substance Abuse Treatment Records Data?
Substance abuse treatment records encompass intake assessments, treatment modalities, patient progress notes, relapse patterns, and recovery outcomes from addiction treatment facilities. These records document psychological, medical, and social components of recovery across multiple provider types—counselors, psychiatrists, social workers, and medical doctors. The data is highly regulated under both HIPAA and 42 CFR Part 2, which provides additional federal protections specific to substance abuse treatment information. Federal law has long required explicit patient consent before releasing these records, reflecting longstanding policy designed to prevent stigma and discrimination from deterring individuals from seeking treatment. Recent regulatory changes have begun easing restrictions to enable broader medical records sharing and research access, while maintaining strict privacy safeguards.
Market Data
USD 2.47 billion
Specialized Substance Abuse EMR Market Size (2024)
Source: LightningStep
USD 4.5 billion
Projected Substance Abuse EMR Market (2032)
Source: LightningStep
USD 36.83 billion by 2032
Global Substance Abuse Treatment Market Projection
Source: LightningStep
Nearly 68%
Treatment Programs Using Basic EMR Functionality
Source: LightningStep
Who Uses This Data
What AI models do with it.do with it.
Addiction Recovery AI & Outcome Analysis
Machine learning platforms analyzing relapse patterns, treatment efficacy across modalities, and predictive recovery indicators to improve clinical protocols and identify high-risk patients early.
Healthcare Researchers & Observational Studies
Independent researchers leveraging de-identified patient health records for large-scale observational studies to illuminate treatment effectiveness questions not covered by drug company clinical trials.
Substance Abuse Treatment Programs
Treatment centers and behavioral health organizations using EMR systems to coordinate care among diverse provider teams, track multi-phase recovery progress, and maintain compliance with specialized regulatory requirements.
Policy & Regulatory Analysis
Government agencies and health policy organizations using aggregated treatment data to inform substance abuse prevention strategies, funding decisions, and regulatory frameworks for addiction services.
What Can You Earn?
What it's worth.worth.
De-identified Research Datasets
Varies
Pricing depends on dataset size, patient cohort specificity, and research use licensing terms; typically negotiated between researchers and data providers.
Real-time Treatment Outcome Feeds
Varies
Subscription-based access for AI platforms and clinical decision support systems; pricing scales with data volume and API usage.
Aggregated Statistical Reports
Varies
One-time or recurring license fees for aggregated treatment modality outcomes and relapse statistics for market research and health system benchmarking.
What Buyers Expect
What makes it valuable.valuable.
42 CFR Part 2 Compliance
Strict adherence to federal substance abuse treatment record privacy rules, including proper de-identification protocols and consent documentation where required by regulation.
HIPAA Security & Business Associate Agreements
Comprehensive encryption, access controls, audit trails, and written business associate agreements that include breach notification procedures and data protection standards.
Clinical Data Completeness
Comprehensive intake assessments, documented treatment protocols, provider progress notes, and outcome indicators across full treatment episodes enabling longitudinal outcome tracking.
De-identification & Privacy Protections
Removal of direct identifiers with attestation to safe harbor or expert determination standards; documented consent chains for any identifiable research use.
Data Accuracy & Provenance
Records sourced from licensed treatment facilities with documented clinical validation; clear documentation of data collection methodology and time periods covered.
Companies Active Here
Who's buying.buying.
Conducting observational studies on treatment efficacy and drug utilization patterns using de-identified patient health records; analyzing outcomes independent of pharmaceutical company influence.
Training machine learning models on real outcome data to improve treatment recommendations, relapse prediction, and clinical decision support for substance abuse programs.
Integrating aggregated outcome benchmarks and treatment protocol libraries into platform offerings to help treatment centers optimize care coordination and track recovery across multiple provider types.
Analyzing treatment program outcomes and service availability to inform SAMHSA regulations, funding allocation, and public health substance abuse strategies.
FAQ
Common questions.questions.
Can I sell patient names and treatment details from substance abuse records?
No. Federal law requires explicit patient consent for any release of substance abuse treatment information, and 42 CFR Part 2 imposes stricter protections than standard HIPAA. Data must be de-identified using safe harbor or expert determination standards before any commercial use without individual consent.
What recent regulatory changes affect substance abuse record sharing?
The final 42 CFR Part 2 rule (effective March 2017 under SAMHSA) allows researchers greater access to substance abuse medical records and lifts the automatic requirement that patient consent be obtained every time records are shared with another healthcare provider, enabling better care coordination while maintaining privacy protections.
What compliance certifications do I need to sell this data?
You must demonstrate HIPAA compliance, 42 CFR Part 2 adherence, and maintain written Business Associate Agreements. Data providers should obtain attestations of de-identification by qualified privacy experts and document all consent chains. State privacy laws may impose additional requirements.
What types of substance abuse treatment data are most valuable?
De-identified longitudinal datasets showing intake assessments, treatment modalities used, patient progress indicators, relapse patterns, and final outcomes across diverse populations are most valuable for AI training and research. Treatment duration, provider types involved, and medication-assisted therapy protocols are particularly sought by outcome analysis platforms.
Sell yoursubstance abuse treatment recordsdata.
If your company generates substance abuse treatment records, AI companies are actively looking for it. We handle pricing, compliance, and buyer matching.
Request Valuation